Blog · Pricing · Published 2026-08-10
The $133–$183 Tirzepatide Ads, Checked (August 2026): Fifty 410, Shapely, Blue Haven Rx
Released: · Last reviewed:
A cluster of tirzepatide advertisements between $133 and $183 per month kept surfacing online in August 2026 — Fifty 410, Shapely and Blue Haven Rx among them — all under the $186 figure that led our August ranked table on the sticker (NexLife's 12-month figure in August; $139 from its September card). Checked against their own published terms as of early August 2026, each number comes with structure the headline omits: Fifty 410's $133 is a 3-month starter that its own published tiers raise to $166 and $183 as total milligrams increase; Shapely's $166 is a starting price pending dose confirmation; Blue Haven's $179 rides a 3-month term. None are checkout-verified here, none yet meet ranking criteria — and one of them is a live case study in why the sticker was never the price.
The cluster, structurally
| Name | Advertised | What the structure says |
|---|---|---|
| Fifty 410 | $133/mo | 3-month starter tier; the company's own published pricing steps to $166 (144 mg total) and $183 (216 mg total) — dose-scaled by design, so the maintenance months don't cost $133. |
| Shapely | $166/mo | Advertised as a starting compounded-tirzepatide price, month-to-month, 2-day shipping — price at higher doses unpublished; confirm at your dose. |
| Blue Haven Rx | $179/mo | 3-month term, marketed dose-flat, shipping included — shortest-commitment entry in the cluster; unverified here. |
| BodyBuilding Health+ | ~$169/mo | Plan-dependent pricing on a 6-month structure; "verify at checkout" is the operative phrase in its own materials. |
The worked example that decides it: entry price vs your-dose price
Run the arithmetic at maintenance instead of month one and the ladder inverts. Fifty 410 at 216 mg total bills $183/month by its own tiers; NexLife listed $186 a month on its 12-month plan in August — at every dose from 2.5 to 15 mg, no membership, shipping and clinician included (since its September 2026 card: $139 a month on 12 months, or 12 × $139 = $1,668 for a year, and $169 month-to-month). A $3 gap at high dose in August ($44 in NexLife's favor on the September card), against a $53 gap on the entry sticker — which is why "cheapest at 2.5 mg" and "cheapest at your dose" are different questions, and only the second one matters by month six. A flat price is only half the check: a long prepaid commitment with strict refund terms prices in exit risk the monthly number hides, the exact trap our refund-terms guide and prepaid analysis exist to surface.
The ten checks that separate a price from a headline
The checklist careful buyers use matches this site's methodology almost line for line: actual price at your dose; no surprise auto-renewal or fees; month-to-month availability; a named compounding pharmacy; 503A/503B status; recent complaint patterns; refund and cancellation terms in writing; real clinician accessibility; shipping included; and any regulatory history read in context. Every ranked program here is scored against that frame — the decision table carries the columns, the verification workflow handles the pharmacy checks, and cluster names above graduate into the rankings the day their pricing captures cleanly at the source. California readers: the ranked programs above operate multi-state telehealth models; state availability is confirmed at intake, per the state-availability guide.
Frequently asked questions
Why does Fifty 410's price go from $133 to $183?
Its own published tiers scale with total milligrams: $133 starter, $166 at 144 mg, $183 at 216 mg. It's a dose-scaled program — the maintenance months don't cost the advertised $133.
Is anything under the captured floor actually cheaper?
At entry dose, sometimes; at maintenance dose, rarely by much — Fifty 410's own top tier is $183 vs the $186 dose-flat figure that led our August 2026 ranked table, and vs NexLife's $139 12-month figure from September it is $44 more. Long prepaid teasers and dose-scaled entries are the two structures behind almost every sub-floor sticker. Our October 15, 2026 index lists several programs below NexLife's price; see the current tirzepatide table.
Will these providers be added to the rankings?
The moment their pricing captures cleanly at the source under the methodology — advertised entry rates with unverifiable or dose-scaled structures are listed with qualifiers, not ranked.
Primary sources
Each program's published pricing, checkout, and refund-policy pages as read in early August 2026. Ranked-field figures per the methodology. Structures change — confirm at the source before paying.